*  Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation - Zurich Open Repository...
Background: The possibility that allogeneic hematopoietic stem cell transplantation performed across the ABO blood group-barrier is associated with an increase of graft-versus-host disease, in particular endothelial damage, has not been elucidated so far. For this reason, we investigated the level of endothelial cell chimerism after allogeneic hematopoietic stem cell transplantation in order to delineate the role of hematopoietic stem cells in endothelial replacement. Design and Methods: The frequency of donor-derived endothelial cells was analyzed in 52 hematopoietic stem cell transplantation recipients, in 22 normal skin biopsies, in 12 graft-versus-host disease affected skin samples, various tissues from 5 autopsies and 4 ...
  http://www.zora.uzh.ch/id/eprint/38792/
*  Central nervous system graft-versus-host disease (CNS-GvHD) after allogeneic haematopoietic stem cell transplantation --...
A 60-year-old man presented with impaired consciousness and psychomotor agitation after a second allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor for acute myeloid leukaemia. Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical symptoms as well as the radiological abnormalities disappeared. The present report illustrates the difficulties in the diagnosis and the management of CNS-GvHD, a very rare and still challenging neurological complication that can occur after allogeneic HSCT. ...
  http://casereports.bmj.com/content/2018/bcr-2017-221840.abstract?sid=35622aa4-0a71-41ce-a776-ecf146431deb
*  Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia - Full...
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion CD3±CD19 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation.. Purpose: This phase I/II trial is to evaluate the safety and efficacy of fludarabine, cyclophosphamide and antithymocyte globulin with CD3±CD19 depleted graft from haploidentical donors in treating patients with aplastic anemia. ...
  https://clinicaltrials.gov/ct2/show/NCT01105273
*  Alternative Donor Transplants: Haploidentical Hematopoietic Stem Cell Transplantation | The MD Anderson Manual of Medical...
Historically, unmanipulated T-cell-replete haploSCT grafts with conventional graft-versus-host-disease (GVHD) prophylaxis used in the late 1970s were associated with intense bidirectional alloreactivity and unacceptably high morbidity and mortality rates due to hyperacute GVHD and graft rejection (4,5,6). This led in the 1980s to the development of complete ex vivo depletion of T cells using CD34-selected grafts. Complete T-cell depletion has been associated with a lower incidence of acute GVHD (aGVHD); however, this caused delayed immune recovery and was associated with a high nonrelapse mortality (NRM) from infections and higher disease relapse rates given the decreased graft-versus-leukemia effect, as well as a higher rate of graft rejection (7,8,9). While graft rejection was partially overcome with "megadoses" of CD34 cells (typically >107 CD34+ cells/kg) and a myeloablative conditioning regimen (including total-body ...
  http://hemonc.mhmedical.com/content.aspx?bookid=1772§ionid=121898074
*  Global Pipeline Drugs for Hematopoietic Stem Cell Transplantation to Grow at a CAGR of XX% between 2017 and 2022 According to...
Global Pipeline Drugs for Hematopoietic Stem Cell Transplantation Industry 2022 Market Research Report" Purchase This Report by calling ResearchnReports.com at +1-888-631-6977.. This report studies the global Pipeline Drugs for Hematopoietic Stem Cell Transplantation market, analyzes and researches the Pipeline Drugs for Hematopoietic Stem Cell Transplantation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like. Actimab-B. Balixafortide. BL-8040. Burixafor. Casin. CDX-301. CordSafe. Download sample pages of this report: https://www.researchnreports.com/request_sample.php?id=64765. The market research report helps analyze the Pipeline Drugs for Hematopoietic Stem ...
  https://www.medgadget.com/2017/04/global-pipeline-drugs-for-hematopoietic-stem-cell-transplantation-to-grow-at-a-cagr-of-xx-between-2017-and-2022-according-to-new-research-report.html
*  Quality of Life and its Determinants among Allogeneic Haematopoietic Stem Cell Transplantation Patients and the Finnish...
This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited ...
  https://helda.helsinki.fi/handle/10138/23443
*  Lymphoid reconstitution following hematopoietic stem cell transplantation. Of mice and men: progress made in HSCT immunobiology...
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings ...
  https://www.paediatrics.ox.ac.uk/publications/309039
*  Hematopoietic Stem Cells Transplantation Market Worth Will Be $7,796.1 Million By 2022: Credence Research - ABNewswire - Press...
The latest market report published by Credence Research, Inc. "Global Hematopoietic Stem Cells Transplantation Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022," the hematopoietic stem cells transplantation market was valued at USD 3,741.3 Mn in 2015, and is expected to reach USD 7,796.1 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.. Market Insights. Over 50 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell ...
  http://www.abnewswire.com/pressreleases/hematopoietic-stem-cells-transplantation-market-worth-will-be-77961-million-by-2022-credence-research_71269.html
*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Tabular View - ClinicalTrials.gov
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of ...
  https://clinicaltrials.gov/ct2/show/record/NCT00730314
*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Full Text View - ClinicalTrials...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of ...
  https://clinicaltrials.gov/ct2/show/NCT00730314?recr=Open&cond=%22Communication+Disorders%22&rank=15
*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Full Text View - ClinicalTrials...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of ...
  https://clinicaltrials.gov/ct2/show/NCT00730314?recr=Open&cond=%22Granulomatous+Disease%2C+Chronic%22&rank=10
*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Full Text View - ClinicalTrials...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of ...
  https://clinicaltrials.gov/ct2/show/NCT00730314?recr=Open&cond=%22Language+Disorders%22&rank=17
*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Full Text View - ClinicalTrials...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of ...
  https://clinicaltrials.gov/ct2/show/NCT00730314?recr=Open&cond=%22Speech+Disorders%22&rank=14
*  Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells - Full Text View - ClinicalTrials...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of ...
  https://clinicaltrials.gov/ct2/show/NCT00730314?term=Niemann-Pick+Disease&rank=10
*  Letermovir for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell...
Letermovir for preventing cytomegalovirus infection in sero-positive patients having allogeneic haematopoietic stem cell transplantation (1153)
  https://www.nice.org.uk/guidance/indevelopment/gid-ta10195
*  Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia - Full Text View - ClinicalTrials.gov
Rationale: Fludarabine, cyclophosphamide, anti-thymocyte globulin and low-dose total body irradiation (LD-TBI) may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion of CD3 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation.. Purpose: Phase II trials to evaluate the efficacy of haploidentical stem cell transplantation with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for children with acquired severe aplastic anemia ...
  https://clinicaltrials.gov/ct2/show/NCT01759732?recr=Open&cond=%22Anemia%2C+Aplastic%22&rank=14
*  Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk...
Extramedullary relapse of AML following allogeneic HSCT remains a poorly understood post-HSCT outcome. The incidence of extramedullary relapse in this study (10%) is consistent with previously reported rates over the past 35 years despite many changes in allogeneic HSCT practices.21,22 Although it is possible that patients with risk factors for extramedullary relapse are currently more likely to undergo allogeneic HSCT than they were in the past, it is more likely that the stable incidence reflects a lack of progress in this scenario. In this series of patients, we confirmed that the increased risk of extramedullary relapse for most previously reported risk factors, including pre-HSCT extramedullary disease, FAB M4/M5 AML, and advanced disease status, also apply to the post-HSCT setting.10,20 We did not, however, find there was an increased risk associated with CD56 or T-cell marker expression. While not surprising, our finding that patients with advanced disease status or high risk ...
  http://www.haematologica.org/content/98/2/179
*  Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia |...
Fanconi anemia is a rare and heterogeneous inherited disorder. The natural history of FA is characterized by marrow failure and a risk for clonal evolution. Evolution to acute myeloid leukemia is the main cause of premature mortality. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is considered the treatment of choice in this situation but the evolution is usually poor post-HSCT (due to treatment-related mortality). From August 2006 to December 2011, 6 consecutive patients with FA who received a sequential treatment with chemotherapy and reduced-intensity conditioning for clonal evolution in four different French institutions were reviewed. Five patients presented an AML and one a myelodysplastic syndrome. The sequential strategy consisted of a pre-transplant chemotherapy by fludarabine 30 mg/m2/d 5 days and cytarabine 1gr/m2x2/d 5 days with granulocyte-colony stimulating factor injections (FLAG) followed early after by a ...
  http://www.haematologica.org/content/early/2014/07/21/haematol.2013.098954
*  Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European...
PURPOSE: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p-CLL. PATIENTS AND METHODS: Baseline data from patients, for whom information on the presence of 17p-CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. RESULTS: A total of 44 patients with 17p-CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p-CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of ...
  http://repository.ubn.ru.nl/handle/2066/69689
*  Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic...
PROTOCOL OUTLINE: Patients receive oral busulfan twice a day on days -9 to -6; cyclophosphamide IV over 1 hour on days -5 to -2; etoposide IV over 4 hours on days -5 to -3; and anti-thymocyte globulin IV twice a day on days -2 and -1 and days 1 and 2. Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Filgrastim (G-CSF) is administered subcutaneously beginning on day 1 and continuing until blood counts recover. Patients receive graft versus host disease prophylaxis with methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1-4 hours (orally once the patients resumes eating) every 12 hours (every 8 hours for pediatric patients) starting on or prior to day -3 and continuing up to 1 year.. Patients are followed at days 28 and 100, at 6 months and 1 year, and then annually for 5 years. ...
  https://clinicaltrials.gov/ct2/show/NCT00006056
*  Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer - Full Text View ...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.. PURPOSE: Phase I/II trial to study the effectiveness of pentostatin followed by peripheral stem cell transplantation in treating patients who have advanced kidney cancer. ...
  https://clinicaltrials.gov/ct2/show/NCT00006968